Scilex Holding Company Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SCLX, updated each market day.
SCLX AI Sentiment
AI predicts Scilex Holding Company Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Scilex Holding Company Common Stock
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Sector
Exchange
Market Cap
$49,301,358
Cap Tier
Employees
30
Headquarters
PALO ALTO, CA
Listed Since
Nov. 11, 2022
Website
SCLX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SCLX Volatility
Scilex Holding Company Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
